Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers
Contact
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers

Daily Archives: April 11, 2019

Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

Press ReleaseBy Sensei TeamApril 11, 2019

– Company brings together world-recognized leaders in immunobiology, cancer biology, and clinical and translational medicine –

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the formation of a new Immuno-Oncology Advisory …

© 2020 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top